Compare CSX Corporation (CSX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Sana Biotechnology Inc — how do they compare? CSX Corporation trades at $47.26 (market cap $87.70B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: CSX Corporation is far larger — about 104.8× Sana Biotechnology Inc's market cap, and CSX Corporation pays a 1.18% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Sana Biotechnology Inc for 23 Days on average.
| CSX | SANA | |
|---|---|---|
Market Cap | $87.70B | $836.71M |
Volume | 6,980,781 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $53.21 | $5.92 |
52-Week Low | $33.68 | $2.68 |
Typical Hold Time | 55 Days | 23 Days |
Enterprise Value | $105.66B | $749.96M |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.34, up 1.13% today, with a bullish technical signal and strong institutional interest. Recent earnings beat expectations in Q1 and Q2 2026, though revenue and net income have declined since 2022. The stock is supported by a 58.69% analyst buy rating and a consensus price target of $51.00, with upcoming Q3 2026 earnings on October 21, 2026, as a key catalyst.
The outlook is positive due to pricing power in freight rail and dividend growth, but risks include declining profit margins, high debt levels, and economic sensitivity. Upside potential exists if earnings rebound, yet valuation multiples are elevated, warranting caution near-term.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
